Asset
PEMBROLIZUMAB
NovoCure Limited Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04892472 | phase2 | terminated | 2021-07-12 | 2025-01-10 | NovoCure GmbH | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer |
| NCT06556563 | phase3 | recruiting | 2025-02-03 | 2029-04-01 | NovoCure GmbH | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma |
| NCT06216301 | phase3 | recruiting | 2024-07-31 | 2028-10-01 | NovoCure GmbH | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC |
| NCT06558799 | phase2 | terminated | 2024-10-14 | 2026-02-23 | NovoCure GmbH | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) |
FDA applications (0)
This company has no applications containing this asset.